Your browser doesn't support javascript.
loading
Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
Pu, Chunlan; Tong, Yu; Liu, Yuanyuan; Lan, Suke; Wang, Shirui; Yan, Guoyi; Zhang, Hongjia; Luo, Dan; Ma, Xinyu; Yu, Su; Huang, Qing; Deng, Rui; Li, Rui.
Afiliação
  • Pu C; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China; Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Secon
  • Tong Y; West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education, Chengdu, Sichuan Province, China.
  • Liu Y; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Lan S; College of Chemistry & Environment Protection Engineering, Southwest Minzu University, Chengdu, China.
  • Wang S; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Yan G; School of Pharmacy, Xinxiang University, Henan, 4453000, China.
  • Zhang H; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Luo D; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Ma X; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Yu S; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Huang Q; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Deng R; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
  • Li R; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China. Electronic address: lirui@scu.edu.cn.
Eur J Med Chem ; 236: 114321, 2022 Jun 05.
Article em En | MEDLINE | ID: mdl-35430559
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Neoplasias de Mama Triplo Negativas / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Neoplasias de Mama Triplo Negativas / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article